Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide in Relapsed/Refractory Neuroblastoma
NCT00276679Phase 2Completed
- Sponsor
- Children's Cancer and Leukaemia Group
- Start
- Apr 2003
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in neuroblastoma, sponsored by Children's Cancer and Leukaemia Group. Primary endpoint: Anti-tumor Activity (Objective Response Rate). Started Apr 2003; status: completed.
02
Drugs
temozolomide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00276679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276679.